PROGNOSTIC SIGNIFICANCE OF SST2 IN HEART FAILURE WITH REDUCED EJECTION FRACTION, A BIOMARKER OF CARDIOVASCULAR MORTALITY AND REHOSPITALIZATION.

Introduction: Heart failure (HF) poses a substantial burden on healthcare systems and society, necessitating effective diagnostic tools for enhanced patient management. The soluble suppression of tumorigenesis 2 protein (Soluble Suppression of Tumorigenesis 2 (sST2)) has emerged as a promising biomarker linked to cardiac remodeling and fibrosis. This study investigates Soluble Suppression of Tumorigenesis 2 (sST2)'s potential as a diagnostic and prognostic marker for chronic heart failure (CHF) and explores its clinical utility in predicting outcomes.

May Measurement Month 2021: an analysis of blood pressure screening results from Georgia.

The annual global May Measurement Month screening campaign initiated by the International Society of Hypertension aims to raise awareness of raised blood pressure (BP) and in the absence of systematic screening is a useful surrogate indicating the size of the problem of hypertension in the general population in Georgia. May Measurement Month screening was carried out at 400 sites in Georgia in 2021, and more than 500 volunteers, including physicians (80%) and medical students (20%), carried out in the screening. Adults aged ≥18 years were recruited opportunistically, and three BP readings were measured, along with a questionnaire collecting information on demographics, lifestyle, and co- morbidities.

Study of some components of the influence and formation of blood flow in patients with "slow flow".

Background: "Slow flow" is one very important concept in modern fundamental and clinical biomedicine. Slow coronary flow is indicative of delayed filling of the terminal coronary artery vessels, occurring in the absence of significant coronary stenosis. This group patient of patients exhibits a high incidence of disability and represents a significant financial and material burden for the state and the healthcare system in general.

May Measurement Month 2019: blood pressure screening results in Georgia, Europe.

May Measurement Month is a global campaign aimed at raising public awareness of hypertension and to improve the management of hypertension-the main risk factor for cardiovascular diseases in the population. Screening was carried out at 400 sites on a national scale. More than 500 volunteers, including physicians (80%) and students of medical universities (20%) participated in the screening.

May Measurement Month 2018: an analysis of blood pressure screening results in Georgia.

May Measurement Month (MMM) is aimed at raising public awareness about arterial hypertension-the main risk factor for cardiovascular diseases in the population. Screening was carried out at 200 sites on a national scale. More than 500 volunteers, including doctors (80%) and medical students (20%) participated in the screening.